Faiez Zannad Selected Research

Hypotension (Low Blood Pressure)

1/2022	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
10/2021	Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
1/2021	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
1/2021	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
1/2020	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study.
1/2020	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
10/2019	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
10/2013	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.
7/2013	Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
3/2013	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Faiez Zannad Research Topics

Disease

378	Heart Failure 10/2022 - 04/2003
82	Myocardial Infarction 04/2022 - 04/2003
46	Hypertension (High Blood Pressure) 11/2021 - 01/2000
43	Fibrosis (Cirrhosis) 06/2022 - 01/2005
35	Cardiovascular Diseases (Cardiovascular Disease) 06/2022 - 01/2005
35	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2000
32	Left Ventricular Dysfunction 04/2022 - 04/2003
29	Stroke (Strokes) 01/2022 - 05/2008
28	Inflammation (Inflammations) 06/2022 - 07/2007
25	Acute Coronary Syndrome 01/2021 - 10/2011
22	Atrial Fibrillation 04/2022 - 10/2006
22	Hyperkalemia 01/2022 - 04/2003
20	Chronic Renal Insufficiency 01/2022 - 06/2010
20	Systolic Heart Failure 01/2021 - 08/2003
19	Diabetes Mellitus 01/2021 - 07/2011
16	Coronary Artery Disease (Coronary Atherosclerosis) 10/2021 - 09/2007
13	Hypotension (Low Blood Pressure) 01/2022 - 07/2011
11	Body Weight (Weight, Body) 04/2022 - 05/2005
10	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2020 - 08/2005
9	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 01/2000
9	Respiratory Sounds (Crackle) 01/2022 - 04/2010
9	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 05/2005
9	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2005
9	Coronary Disease (Coronary Heart Disease) 11/2021 - 05/2008
8	Heart Diseases (Heart Disease) 01/2022 - 03/2012
8	Dyspnea (Shortness of Breath) 10/2019 - 03/2007
7	Hypertrophy 01/2022 - 10/2003
7	Neoplasms (Cancer) 01/2022 - 01/2011
7	Atherosclerosis 01/2021 - 02/2004
6	Weight Loss (Weight Reduction) 04/2022 - 09/2002
6	Obesity 01/2022 - 07/2005
6	Sudden Death 10/2021 - 01/2005
6	Renal Insufficiency (Renal Failure) 01/2021 - 11/2012
6	Cardiac Arrhythmias (Arrythmia) 01/2021 - 07/2011
6	Albuminuria 01/2021 - 10/2003
6	Disease Progression 01/2021 - 06/2006
6	ST Elevation Myocardial Infarction 02/2020 - 03/2014
6	Hypokalemia 01/2020 - 04/2003
6	Edema (Dropsy) 10/2019 - 08/2004

Drug/Important Bio-Agent (IBA)

81	Biomarkers (Surrogate Marker)IBA 10/2022 - 03/2006
55	Eplerenone (Inspra)FDA LinkGeneric 04/2022 - 04/2003
49	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 04/2007
43	empagliflozinIBA 10/2022 - 01/2017
43	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2022 - 09/2007
30	Spironolactone (Aldactone)FDA LinkGeneric 04/2022 - 04/2011
29	Vasopressins (Vasopressin)IBA 01/2018 - 05/2005
28	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 06/2021 - 10/2002
28	Tolvaptan FDA Link 01/2018 - 05/2005
27	pro-brain natriuretic peptide (1-76)IBA 10/2022 - 10/2009
26	PotassiumIBA 01/2022 - 10/2003
26	AldosteroneIBA 01/2020 - 04/2003
25	Pharmaceutical PreparationsIBA 03/2022 - 03/2006
25	Natriuretic PeptidesIBA 01/2022 - 09/2008
20	SodiumIBA 04/2022 - 03/2007
20	CreatinineIBA 01/2022 - 04/2010
20	CollagenIBA 01/2022 - 01/2005
20	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 01/2017
20	Angiotensin Receptor AntagonistsIBA 06/2021 - 11/2005
18	DiureticsIBA 04/2022 - 03/2007
16	alogliptinIBA 07/2021 - 10/2011
15	Valsartan (Vals)FDA Link 01/2022 - 11/2005
14	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2019
14	Neprilysin (Neutral Endopeptidase)IBA 01/2022 - 01/2017
13	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2005
12	C-Reactive ProteinIBA 06/2022 - 07/2007
12	paragonIBA 01/2022 - 01/2017
12	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 01/2000
12	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021 - 03/2015
11	Biological ProductsIBA 06/2022 - 07/2013
10	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 08/2021 - 08/2013
10	RivaroxabanIBA 01/2021 - 11/2013
10	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2020 - 10/2002
9	AlbuminsIBA 10/2022 - 01/2000
9	Sodium-Glucose Transport ProteinsIBA 02/2022 - 01/2017
9	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 01/2017
9	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2022 - 01/2005
8	Galectin 3 (LGALS3)IBA 06/2022 - 01/2012
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 02/2004
7	Procollagen Type IIBA 06/2022 - 09/2007
7	AngiotensinsIBA 01/2022 - 02/2009
7	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2005
7	omega-Chloroacetophenone (Mace)IBA 10/2021 - 01/2013
7	aliskiren FDA Link 01/2018 - 01/2011
6	Peptides (Polypeptides)IBA 06/2022 - 01/2005
6	Collagen Type I (Type I Collagen)IBA 01/2022 - 05/2009
6	TroponinIBA 07/2021 - 01/2018
6	finerenoneIBA 01/2021 - 06/2012
6	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 10/2011
6	Rosuvastatin Calcium (Crestor)FDA Link 01/2018 - 05/2005
5	Troponin T (Troponin T1)IBA 10/2022 - 01/2021
5	Insulin (Novolin)FDA Link 10/2022 - 07/2005
5	procollagen type I carboxy terminal peptide (PICP)IBA 06/2022 - 01/2019
5	Growth Differentiation Factor 15IBA 01/2022 - 10/2017
5	SymportersIBA 12/2021 - 11/2017
5	LipidsIBA 01/2021 - 05/2005

Therapy/Procedure

142	Therapeutics 08/2022 - 04/2003
10	Renal Dialysis (Hemodialysis) 06/2022 - 04/2009
8	Drug Therapy (Chemotherapy) 01/2021 - 01/2005
7	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 10/2019 - 09/2007
5	Patient Readmission 10/2021 - 04/2010